Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgian Uro-Oncological Study Group

J Urol. 1995 Aug;154(2 Pt 1):429-34. doi: 10.1097/00005392-199508000-00027.


Purpose: We investigated the effect of neoadjuvant treatment before radical prostatectomy for clinically localized prostate cancer.

Materials and methods: A total of 130 patients with stages T2b and T3 prostate cancer was randomized in a multicenter study: 62 underwent immediate radical prostatectomy and 65 received 560 mg. estramustine phosphate daily for 6 weeks preoperatively.

Results: For clinical stage T2b tumors the neoadjuvant treatment resulted in a significant decrease in positive surgical margins compared to the nonpretreated group. This difference was not found for clinical stage T3 tumors. The impact on progression and survival still must be analyzed.

Conclusions: Neoadjuvant treatment can be beneficial for clinical stage T2 prostate cancer. Optimal treatment for stage T3 tumors remains controversial.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Chemotherapy, Adjuvant
  • Estramustine / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Preoperative Care*
  • Prospective Studies
  • Prostate-Specific Antigen / blood
  • Prostatectomy*
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery*


  • Estramustine
  • Prostate-Specific Antigen